GSK, Human Genome Escalate $2.6B Buyout Battle
Pharmaceutical giant GSK, which has been courting HGS since April, extended its offer's expiration date for the second time Friday, when it was supposed to expire, giving the company until July 20 to accept the $13 per share deal for all of its outstanding shares.
“Extension of the tender offer...
Already a subscriber? Click here to login